Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Pelvic Neoplasms 1Colorectal Neoplasms 1Chylous Ascites 1Abdominal Neoplasms 1

Interventions

Specimen Handling 276pembrolizumab 227Magnetic Resonance Spectroscopy 226Carboplatin 180Cisplatin 166Biopsy 166Nivolumab 158Cyclophosphamide 144Radiotherapy 125Paclitaxel 124Gemcitabine 116Bevacizumab 95durvalumab 92Dexamethasone 88Rituximab 81Oxaliplatin 80venetoclax 75atezolizumab 71Fluorouracil 70Docetaxel 70Capecitabine 70Doxorubicin 68Etoposide 65Radiosurgery 64Ipilimumab 63Radiation 61Prednisone 60Cytarabine 60Lenalidomide 58Pemetrexed 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Embolization, Therapeutic × 90 days × Clear all
NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Mayo Clinic

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06820320 2026-03-06

Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Completed
42 enrolled
Gynecologic

Abdominal Neoplasms, Chylous Ascites, Pelvic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡